Review



k0237  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress k0237
    K0237, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k0237/Anti-HA+Magnetic+Agarose+Beads/pm41944334-244-24-21
    Average 94 stars, based on 5 article reviews
    k0237 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: ELABELA Targets Mitochondria to Modulate Heart Development.
    Article Snippet: .. After 48 h, cells were lysed and the supernatants were incubated overnight at 4◦C with anti-HA and anti-Flag antibody-conjugated agarose beads (MCE, HY-K0236 and HY-K0237). ..



    Similar Products

    94
    MedChemExpress k0237
    K0237, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k0237/Anti-HA+Magnetic+Agarose+Beads/pm41944334-244-24-21
    Average 94 stars, based on 1 article reviews
    k0237 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress anti ha magnetic beads
    Anti Ha Magnetic Beads, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k0237/Anti-HA+Magnetic+Agarose+Beads/pmc12297473-534-28-31
    Average 94 stars, based on 1 article reviews
    anti ha magnetic beads - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress group ha wnt5a
    a Venn diagram analysis of differentially expressed WNT family genes comparing human (blue) and mouse (red) transcriptomes. b qPCR analysis of the expression of <t>WNT16,</t> <t>WNT5A,</t> and WNT9A in human myometrial and mouse uterine scar tissues. c WB analysis of WNT5A levels in human myometrial tissues. d Immunofluorescence imaging and plot profile analysis delineate the co-localization of sFRP2 with WNT5A in the human myometrium with US ( n = 6 samples). e , f WB ( e ) and immunofluorescence ( f ) analyses of WNT5A in hUFIBs ( n = 6 samples). g WB analysis of WNT5A in hUFIBs following sFRP2 overexpression (sFRP2OE), PBS-treated hUFIBs (WT), and negative control lentivector-treated hUFIBs (Control). h WB bands illustrate WNT5A levels in sFRP2-knockdown hUFIBs with TGF-β. WT cells received PBS and TGF-β, while control cells were treated with scramble shRNA and TGF-β. i WNT5A concentrations in conditioned media (CM) derived from WT, Control, and sFRP2OE groups, as well as corresponding heparinase-supplemented counterparts. j Immunoprecipitation (IP) assay indicates the interaction between <t>FLAG-sFRP2</t> and HA-WNT5A in normal hUFIBs. k – m WB ( k , l ) and immunofluorescence ( m , n = 6 samples) analyses of fibrinogen, Col1A1, and Col3A1 in hUFIBs after WNT5A stimulation, using PBS as the control treatment. n , o Immunofluorescence ( n , n = 6 samples) and flow cytometric ( o ) analyses illustrate Ca 2+ influx (stained with Fluro-4 AM) in hUFIBs. p Flow cytometric quantification of Ca 2+ influx in hUFIBs subjected to different treatments. q Immunofluorescence analysis of the relationship of sFRP2 with Ca 2+ and fibrinogen in sFRP2OE hUFIBs ( n = 6 samples). r Dynamic tracing of Ca 2+ influx in hUFIBs of sFRP2KD, WT, and Control groups with TGF-β ( n = 6 samples). Box plots in b , i , l , o , p illustrate data distributions ( n = 6 samples), with the central lines representing the mean, box boundaries indicating standard deviation, and whiskers showing the minimum and maximum values. The p values were calculated by two-tailed unpaired t -tests for two groups and one-way ANOVA with post hoc LSD tests for multiple groups. Source data are provided as a Source Data file.
    Group Ha Wnt5a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k0237/Anti-HA+Magnetic+Agarose+Beads/pmc12297473-534-18-31
    Average 94 stars, based on 1 article reviews
    group ha wnt5a - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    a Venn diagram analysis of differentially expressed WNT family genes comparing human (blue) and mouse (red) transcriptomes. b qPCR analysis of the expression of WNT16, WNT5A, and WNT9A in human myometrial and mouse uterine scar tissues. c WB analysis of WNT5A levels in human myometrial tissues. d Immunofluorescence imaging and plot profile analysis delineate the co-localization of sFRP2 with WNT5A in the human myometrium with US ( n = 6 samples). e , f WB ( e ) and immunofluorescence ( f ) analyses of WNT5A in hUFIBs ( n = 6 samples). g WB analysis of WNT5A in hUFIBs following sFRP2 overexpression (sFRP2OE), PBS-treated hUFIBs (WT), and negative control lentivector-treated hUFIBs (Control). h WB bands illustrate WNT5A levels in sFRP2-knockdown hUFIBs with TGF-β. WT cells received PBS and TGF-β, while control cells were treated with scramble shRNA and TGF-β. i WNT5A concentrations in conditioned media (CM) derived from WT, Control, and sFRP2OE groups, as well as corresponding heparinase-supplemented counterparts. j Immunoprecipitation (IP) assay indicates the interaction between FLAG-sFRP2 and HA-WNT5A in normal hUFIBs. k – m WB ( k , l ) and immunofluorescence ( m , n = 6 samples) analyses of fibrinogen, Col1A1, and Col3A1 in hUFIBs after WNT5A stimulation, using PBS as the control treatment. n , o Immunofluorescence ( n , n = 6 samples) and flow cytometric ( o ) analyses illustrate Ca 2+ influx (stained with Fluro-4 AM) in hUFIBs. p Flow cytometric quantification of Ca 2+ influx in hUFIBs subjected to different treatments. q Immunofluorescence analysis of the relationship of sFRP2 with Ca 2+ and fibrinogen in sFRP2OE hUFIBs ( n = 6 samples). r Dynamic tracing of Ca 2+ influx in hUFIBs of sFRP2KD, WT, and Control groups with TGF-β ( n = 6 samples). Box plots in b , i , l , o , p illustrate data distributions ( n = 6 samples), with the central lines representing the mean, box boundaries indicating standard deviation, and whiskers showing the minimum and maximum values. The p values were calculated by two-tailed unpaired t -tests for two groups and one-way ANOVA with post hoc LSD tests for multiple groups. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Identifying fibroblast-derived sFRP2 as a therapeutic target and engineering siRNA therapy for uterine scarring

    doi: 10.1038/s41467-025-62248-1

    Figure Lengend Snippet: a Venn diagram analysis of differentially expressed WNT family genes comparing human (blue) and mouse (red) transcriptomes. b qPCR analysis of the expression of WNT16, WNT5A, and WNT9A in human myometrial and mouse uterine scar tissues. c WB analysis of WNT5A levels in human myometrial tissues. d Immunofluorescence imaging and plot profile analysis delineate the co-localization of sFRP2 with WNT5A in the human myometrium with US ( n = 6 samples). e , f WB ( e ) and immunofluorescence ( f ) analyses of WNT5A in hUFIBs ( n = 6 samples). g WB analysis of WNT5A in hUFIBs following sFRP2 overexpression (sFRP2OE), PBS-treated hUFIBs (WT), and negative control lentivector-treated hUFIBs (Control). h WB bands illustrate WNT5A levels in sFRP2-knockdown hUFIBs with TGF-β. WT cells received PBS and TGF-β, while control cells were treated with scramble shRNA and TGF-β. i WNT5A concentrations in conditioned media (CM) derived from WT, Control, and sFRP2OE groups, as well as corresponding heparinase-supplemented counterparts. j Immunoprecipitation (IP) assay indicates the interaction between FLAG-sFRP2 and HA-WNT5A in normal hUFIBs. k – m WB ( k , l ) and immunofluorescence ( m , n = 6 samples) analyses of fibrinogen, Col1A1, and Col3A1 in hUFIBs after WNT5A stimulation, using PBS as the control treatment. n , o Immunofluorescence ( n , n = 6 samples) and flow cytometric ( o ) analyses illustrate Ca 2+ influx (stained with Fluro-4 AM) in hUFIBs. p Flow cytometric quantification of Ca 2+ influx in hUFIBs subjected to different treatments. q Immunofluorescence analysis of the relationship of sFRP2 with Ca 2+ and fibrinogen in sFRP2OE hUFIBs ( n = 6 samples). r Dynamic tracing of Ca 2+ influx in hUFIBs of sFRP2KD, WT, and Control groups with TGF-β ( n = 6 samples). Box plots in b , i , l , o , p illustrate data distributions ( n = 6 samples), with the central lines representing the mean, box boundaries indicating standard deviation, and whiskers showing the minimum and maximum values. The p values were calculated by two-tailed unpaired t -tests for two groups and one-way ANOVA with post hoc LSD tests for multiple groups. Source data are provided as a Source Data file.

    Article Snippet: For immunoprecipitation assay, 500 μg of total protein from cell lysis in each group (Control, HA-WNT5A-transfected cells, FLAG-sFRP2-transfected cells, or HA-WNT5A/FLAG-sFRP2-cotransfected cells) was incubated with 20 μL of anti-HA magnetic beads (MedChemExpress, HY-K0237) or anti-FLAG magnetic beads (MedChemExpress, HY-K0207) at 4 °C with gentle rotation overnight.

    Techniques: Expressing, Immunofluorescence, Imaging, Over Expression, Negative Control, Control, Knockdown, shRNA, Derivative Assay, Immunoprecipitation, Staining, Standard Deviation, Two Tailed Test